Shots:Elanco has granted Neurizon exclusive global rights to monepantel’s data package & related IP to develop & commercialize NUZ-001 & related compounds for the treatment, prevention, or palliation of ALS & other neurodegenerative diseases in humansAs per the deal, Elanco will receive an upfront payment, development milestone payments of $9.75M for the initial…
